PL2719699T3 - Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania - Google Patents

Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania

Info

Publication number
PL2719699T3
PL2719699T3 PL13198224T PL13198224T PL2719699T3 PL 2719699 T3 PL2719699 T3 PL 2719699T3 PL 13198224 T PL13198224 T PL 13198224T PL 13198224 T PL13198224 T PL 13198224T PL 2719699 T3 PL2719699 T3 PL 2719699T3
Authority
PL
Poland
Prior art keywords
triazolopyrazines
compositions
methods
certain
use therefor
Prior art date
Application number
PL13198224T
Other languages
English (en)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2719699(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of PL2719699T3 publication Critical patent/PL2719699T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
PL13198224T 2009-12-31 2010-12-30 Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania PL2719699T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
EP13198224.1A EP2719699B1 (en) 2009-12-31 2010-12-30 Certain triazolopyrazines, compositions thereof and methods of use therefor
EP10840591.1A EP2519524A4 (en) 2009-12-31 2010-12-30 CERTAIN TRIAZOLOPYRIDINE AND TRIAZOLOPYRZINE, COMPOSITIONS AND METHOD OF USE

Publications (1)

Publication Number Publication Date
PL2719699T3 true PL2719699T3 (pl) 2016-01-29

Family

ID=44226181

Family Applications (3)

Application Number Title Priority Date Filing Date
PL13198224T PL2719699T3 (pl) 2009-12-31 2010-12-30 Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
PL20199091.8T PL3795573T3 (pl) 2009-12-31 2010-12-30 Niektóre triazolopirazyny, ich kompozycje i sposoby ich zastosowania
PL19151824T PL3511330T3 (pl) 2009-12-31 2010-12-30 Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL20199091.8T PL3795573T3 (pl) 2009-12-31 2010-12-30 Niektóre triazolopirazyny, ich kompozycje i sposoby ich zastosowania
PL19151824T PL3511330T3 (pl) 2009-12-31 2010-12-30 Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met

Country Status (38)

Country Link
US (9) US8987269B2 (pl)
EP (5) EP3795573B1 (pl)
JP (5) JP5337313B2 (pl)
KR (3) KR101905350B1 (pl)
CN (3) CN106117248B (pl)
AU (2) AU2010338712B2 (pl)
BR (1) BR112012016129B1 (pl)
CA (1) CA2785749C (pl)
CL (1) CL2012001752A1 (pl)
CO (1) CO6612235A2 (pl)
CU (1) CU24167B1 (pl)
CY (2) CY1118250T1 (pl)
DK (3) DK2719699T3 (pl)
DO (1) DOP2012000188A (pl)
EA (2) EA030141B1 (pl)
EC (1) ECSP12012011A (pl)
ES (4) ES2840454T3 (pl)
GT (1) GT201200220A (pl)
HR (3) HRP20221090T1 (pl)
HU (3) HUE052828T2 (pl)
IL (2) IL220433B (pl)
LT (1) LT3795573T (pl)
ME (1) ME02211B (pl)
MX (2) MX336996B (pl)
MY (1) MY179933A (pl)
NI (1) NI201200118A (pl)
NZ (1) NZ601128A (pl)
PE (3) PE20160588A1 (pl)
PH (1) PH12012501355A1 (pl)
PL (3) PL2719699T3 (pl)
PT (3) PT3795573T (pl)
RS (3) RS63612B1 (pl)
SG (1) SG181781A1 (pl)
SI (2) SI2719699T1 (pl)
SM (3) SMT202000693T1 (pl)
UA (1) UA107822C2 (pl)
WO (1) WO2011079804A1 (pl)
ZA (1) ZA201205730B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2840454T3 (es) * 2009-12-31 2021-07-06 Hutchison Medipharma Ltd Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos
CN107674073B (zh) * 2010-05-17 2021-09-10 印蔻真治疗公司 作为蛋白激酶调节剂的3,5-二取代-3h-咪唑(或[1,2,3]三唑)并[4,5-b] 吡啶化合物
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
US9815831B2 (en) * 2012-03-30 2017-11-14 Rhizen Pharmaceuticals Sa 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
BR112015016580A2 (pt) 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
SI2964638T1 (sl) 2013-03-06 2017-11-30 Astrazeneca Ab Kinazolinski inhibitorji aktiviranja mutantnih oblik receptorja epidermalnega rastnega faktorja
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
AU2013402175B2 (en) * 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
DK3087070T3 (en) * 2013-12-26 2017-12-04 Ignyta Inc PYRAZOLO [1,5-A] PYRIDINE DERIVATIVES AND PROCEDURES FOR THEIR USE
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10344035B2 (en) * 2015-12-31 2019-07-09 Shanghai Phaarmaceuticals Holding Co., Ltd. Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
BR112021003814A2 (pt) 2018-09-11 2021-05-18 Astrazeneca Ab método melhorado para a fabricação de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina e suas formas polimórficas
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
MX2021005012A (es) * 2018-10-30 2021-07-21 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.
EP3893872B1 (en) 2018-12-14 2024-07-17 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
EP3898617A4 (en) 2018-12-17 2022-08-17 Achillion Pharmaceuticals, Inc. TARGETED DOSAGE FOR THE TREATMENT OF COMPLEMENT INDUCED DISORDERS
US12479856B2 (en) 2019-03-22 2025-11-25 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
JP7617076B2 (ja) * 2019-07-22 2025-01-17 リペア セラピューティクス インコーポレイテッド Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体
EP4107166A4 (en) * 2020-02-20 2024-06-26 Achillion Pharmaceuticals, Inc. HETEROARYL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D-MEDIATED DISORDERS
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
JP2023543990A (ja) * 2020-09-28 2023-10-19 コデクシス， インコーポレイテッド キラルアミンを合成するための操作された生体触媒および方法
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
EP4511025A1 (en) * 2022-04-20 2025-02-26 Engrail Therapeutics, Inc. GABAa RECEPTOR MODULATOR SALTS, PARTICLES, AND USES THEREOF
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
EP4561564A2 (en) * 2022-07-29 2025-06-04 Baylor College of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
WO2024148089A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
GB202300923D0 (en) * 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib
WO2024263860A1 (en) * 2023-06-22 2024-12-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2002516326A (ja) * 1998-05-26 2002-06-04 メルク エンド カムパニー インコーポレーテッド イミダゾピリジン系トロンビン阻害薬
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7250417B2 (en) * 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
KR20070053237A (ko) 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 피롤로-피리딘 키나제 조절제
EP1786811A2 (en) 2004-08-18 2007-05-23 Pharmacia & Upjohn Company LLC Triazolopyridine compounds
WO2006087538A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
MX2008007049A (es) * 2005-11-30 2008-10-23 Vertex Pharma Inhibidores de c-met y usos de los mismos.
DK1966214T3 (en) 2005-12-21 2017-02-13 Janssen Pharmaceutica Nv TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
WO2008036272A1 (en) 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
KR20090071612A (ko) 2006-10-23 2009-07-01 에스지엑스 파마슈티컬스, 인코포레이티드 단백질 키나제 조정제로서의 바이시클릭 트리아졸
PL2081937T3 (pl) * 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
MX2009005144A (es) 2006-11-22 2009-05-27 Incyte Corp Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa.
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
US8242280B2 (en) 2007-04-10 2012-08-14 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
WO2009105782A1 (en) * 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Hiv protease inhibitor and cytochrome p450 inhibitor combinations
UY31676A1 (es) 2008-02-28 2009-09-30 "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
US8691838B2 (en) 2008-05-22 2014-04-08 Amgen Inc. Heterocycles as protein kinase inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
EA201200260A1 (ru) * 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002179A (es) * 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
ES2840454T3 (es) 2009-12-31 2021-07-06 Hutchison Medipharma Ltd Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos
CN107674073B (zh) 2010-05-17 2021-09-10 印蔻真治疗公司 作为蛋白激酶调节剂的3,5-二取代-3h-咪唑(或[1,2,3]三唑)并[4,5-b] 吡啶化合物

Also Published As

Publication number Publication date
CL2012001752A1 (es) 2013-01-25
PL3795573T3 (pl) 2022-11-21
KR101434766B1 (ko) 2014-08-26
PE20160588A1 (es) 2016-07-09
DK2719699T3 (en) 2015-08-24
AU2010338712A1 (en) 2012-07-12
EP2519524A1 (en) 2012-11-07
HK1194071A1 (en) 2014-10-10
SMT202000693T1 (it) 2021-01-05
US9956218B2 (en) 2018-05-01
EP2519524A4 (en) 2013-07-03
ECSP12012011A (es) 2012-10-30
JP2013516393A (ja) 2013-05-13
AU2010338712B2 (en) 2015-04-02
BR112012016129A2 (pt) 2016-05-31
EP3511330A1 (en) 2019-07-17
GT201200220A (es) 2014-12-22
HRP20221090T1 (hr) 2022-11-25
PT3511330T (pt) 2020-12-24
US20170027934A1 (en) 2017-02-02
EP3511330B1 (en) 2020-09-30
EP2966075B1 (en) 2019-02-27
IL220433B (en) 2018-01-31
UA107822C2 (xx) 2015-02-25
US20200179377A1 (en) 2020-06-11
CN106432225A (zh) 2017-02-22
AU2015203480A1 (en) 2015-07-16
SMT201500213B (it) 2015-10-30
AU2015203480B2 (en) 2017-10-26
US11896592B2 (en) 2024-02-13
CN106432225B (zh) 2019-02-19
CN102906092A (zh) 2013-01-30
DK3511330T3 (da) 2020-12-21
WO2011079804A1 (en) 2011-07-07
MY179933A (en) 2020-11-19
RS61281B1 (sr) 2021-02-26
CY1123777T1 (el) 2022-03-24
JP6486999B2 (ja) 2019-03-20
HRP20202017T1 (hr) 2021-02-19
CA2785749C (en) 2017-11-28
ES2546635T3 (es) 2015-09-25
LT3795573T (lt) 2022-11-10
MX336996B (es) 2016-02-09
US20250099462A1 (en) 2025-03-27
KR101905350B1 (ko) 2018-11-30
EP2966075A1 (en) 2016-01-13
US8507487B2 (en) 2013-08-13
JP5337313B2 (ja) 2013-11-06
JP6647434B2 (ja) 2020-02-14
JP6194046B2 (ja) 2017-09-06
KR20170098324A (ko) 2017-08-29
EP2719699B1 (en) 2015-07-08
SG181781A1 (en) 2012-07-30
CN102906092B (zh) 2016-08-03
HRP20150952T1 (hr) 2015-10-09
CY1118250T1 (el) 2017-06-28
HK1216880A1 (en) 2016-12-09
ME02211B (me) 2016-02-20
JP2018009004A (ja) 2018-01-18
RS63612B1 (sr) 2022-10-31
HUE052828T2 (hu) 2021-05-28
HUE025504T2 (en) 2016-02-29
JP2016155848A (ja) 2016-09-01
US20180263977A1 (en) 2018-09-20
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
SI3511330T1 (sl) 2021-01-29
DK3795573T3 (da) 2022-09-19
US20120245178A1 (en) 2012-09-27
US20210154192A1 (en) 2021-05-27
BR112012016129B1 (pt) 2020-11-03
US8987269B2 (en) 2015-03-24
US20240139182A1 (en) 2024-05-02
IL239997A0 (en) 2015-08-31
NZ601128A (en) 2014-12-24
CA2785749A1 (en) 2011-07-07
IL239997A (en) 2017-11-30
KR20140059307A (ko) 2014-05-15
MX386852B (es) 2025-03-19
PH12012501355A1 (en) 2012-12-17
PE20130375A1 (es) 2013-04-10
US20120264739A1 (en) 2012-10-18
MX2012007756A (es) 2012-11-06
CN106117248A (zh) 2016-11-16
CN106117248B (zh) 2019-01-22
PT2719699E (pt) 2015-09-30
KR20120125261A (ko) 2012-11-14
PL3511330T3 (pl) 2021-04-19
EA201691461A1 (ru) 2017-01-30
US10512645B2 (en) 2019-12-24
ES2726152T3 (es) 2019-10-02
JP2019108345A (ja) 2019-07-04
ZA201205730B (en) 2016-01-27
KR101771299B1 (ko) 2017-08-24
ES2927146T3 (es) 2022-11-02
CU20120101A7 (es) 2012-10-15
PT3795573T (pt) 2022-09-15
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
SI2719699T1 (sl) 2015-12-31
US20150368271A1 (en) 2015-12-24
EA201200951A1 (ru) 2013-09-30
HUE059696T2 (hu) 2022-12-28
EP2719699A1 (en) 2014-04-16
JP2013209418A (ja) 2013-10-10
SMT202200371T1 (it) 2022-11-18
RS54217B1 (sr) 2015-12-31
EA030141B1 (ru) 2018-06-29
EA025466B1 (ru) 2016-12-30
EP3795573A1 (en) 2021-03-24
CU24167B1 (es) 2016-03-31
US10946014B2 (en) 2021-03-16
CO6612235A2 (es) 2013-02-01
EP3795573B1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
PL2719699T3 (pl) Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
IL250824B (en) Certain amino-pyrimidines, their assemblies, and methods of using them
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
ZA201200226B (en) Opsin-binding ligands, compositions and methods of use
IL217280A0 (en) Compositions comprising combinations of phyto-cannabinoids and uses thereof
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
GB0903299D0 (en) Composition and methods
GB0902429D0 (en) Compositions and their use
GB201210536D0 (en) Composition, use and method of preparation thereof
GB0901494D0 (en) Compositions and Methods
ZA201200260B (en) Polyphenylsulphone-polytetrafluroethylene compositions and use thereof
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
GB0909792D0 (en) Composition and uses thereof
GB0908498D0 (en) Compositions and methods
GB0903913D0 (en) Compositions and methods
GB0907616D0 (en) Methods and compositions
GB0909720D0 (en) Compositions and methods
HK1177735A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
GB0902812D0 (en) Composition and use
IL214333A0 (en) Carbamoylphosphonates as inhibitors and uses thereof